Pacgen, General Biologicals deal

Pacgen will grant General Biologicals exclusive, worldwide rights to develop and commercialize products containing PAC-113 or related peptides to treat oral, vaginal, dermatological and ophthalmic conditions. The deal excludes transitional skin-mucous membrane areas of the mouth. Pacgen will receive an upfront payment and minimum annual royalties independent from sales or development. Pacgen is also eligible for milestones and royalties. The deal is subject to approval by the TSX Venture Exchange and Pacgen shareholders. Pacgen declined to disclose details, and General Biologicals could not be reached. ...